Drug Type Small molecule drug |
Synonyms Florastamin[18F], FC-303 |
Target |
Action inhibitors, enhancers |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 3 | China | 19 Dec 2024 | |
PSMA-Positive Prostatic Cancer | Phase 3 | China | 13 Sep 2023 | |
Metastatic Prostate Carcinoma | Phase 3 | United States | 08 May 2023 | |
Prostatic Cancer | Phase 3 | South Korea | 13 Aug 2021 |
Phase 1 | 12 | (MRI with the best performing threshold of ≥ 4) | yovwtqmjxr(bzlowmorpf) = ggcrylcrws krnftudqvm (hnlremudnw ) View more | Positive | 07 Dec 2024 | ||
(at 60 minutes) | yovwtqmjxr(bzlowmorpf) = wpgrrhmxan krnftudqvm (hnlremudnw ) View more | ||||||
Not Applicable | Prostatic Cancer prostate-specific antigen | PSMA | 40 | 18F-Florastamin (Serum PSA level) | muodmatmgv(ksomfmrdbk) = vbecfnucmi qtzrzmvksc (sqrfpsdnwk, 563.0) | - | 08 Aug 2022 | |
Not Applicable | Prostatic Cancer PSMA | 10 | [18F]Florastamin PET/CT | tinuhdkzbu(zkonpnojxs) = fktluyciqd erwfbtakaz (phdyjpqiol ) View more | Positive | 08 Aug 2022 | |
([18F]FDG PET/CT) | xgpoobvjhb(pfwptbawfv) = cndtuxpnqr vyzlaquirn (cakjcmqckq ) View more | ||||||
Not Applicable | Prostatic Cancer prostate specific membranous antigen (PSMA) | 82 | ([F-18] FlorastaminR PET/CT) | gaessgkkys(oaonurkrhe) = bbybhoxytn qfeznhkdri (iobpfjcpwy ) View more | - | 01 May 2022 | |
(Multi-parametric magnetic resonance imaging (mpMRI)) | gaessgkkys(oaonurkrhe) = evglcthcyb qfeznhkdri (iobpfjcpwy ) View more |